SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review.

Primary outcome Change in serum ALT levels: In all of the studies, there was a decrease in serum ALT levels from the baseline in those treated with SGLT-2 inhibitors (Table 6 ) but in the study done by Shibuya et al[ 13 ] it did not reach statistical significance.

also in 111,027 other papers

Shibuya et al[ 13 ] observed a decrease in ALT that almost reached statistical significance, however data regarding AST was unavailable[ 13 ].

also in 378 other papers